Logo

Ziopharm Signs an Exclusive License Agreement with NIH to Develop and Commercialize TCRs Targeting Neoantigen for Cancer

Share this

Ziopharm Signs an Exclusive License Agreement with NIH to Develop and Commercialize TCRs Targeting Neoantigen for Cancer

Shots:

  • NIH to receive $1.5M upfront- $16.3M as clinical- regulatory & commercial milestones including $3M prior to marketing approval in the US- Europe- Japan- Australia- China & India and $0.1M at the initiation of P-I study- $12M as commercial milestone and royalties on sales of products with $0.046M as reimbursement payment for patent
  • Ziopharm to get exclusive IP rights of two technologies dealing with TCRs against neoantigens in hotspots including mutated KRAS- p53 and EGFR by using Sleeping Beauty platform and manufacturing methods to produce modified T-cells and non-exclusive WW license to certain additional manufacturing technologies
  • The non-viral Sleeping Beauty platform genetically modifies T-Cells with DNA plasmids targeting specific antigen in solid tumors and CARs targeting CD19 in blood cancer. Additionally- Ziopharm is also developing Controlled IL-12 platform in collaboration with Regeneron Pharmaceuticals

Ref: ZioPharma | Image: Talk markets

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions